MERCK PTE. LTD.

**4.1 Therapeutic indications** Bavencio is indicated as monotherapy for the treatment of patients with metastatic Merkel cell carcinoma (MCC). Bavencio is indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy. Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

<p><strong>4.1 Therapeutic indications</strong></p> <p>Concor&reg; AMLO is indicated for treatment of hypertension as substitution therapy in patients adequately controlled with the individual products given concurrently at the same doses level as in the combination, but as separate tablets.</p>

**Therapeutic indications** Pergoveris is indicated for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level < 1.2 international units/l.

**4.1 Therapeutic indications** Rebif is indicated for the treatment of - patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing relapsing multiple sclerosis (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - patients with relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

**Therapeutic indications** Ovidrel® is indicated in the treatment of - Women undergoing superovulation prior to assisted reproductive technologies (ART) such as in vitro fertilisation (IVF): Ovidrel® is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth, - Anovulatory or oligo-ovulatory women: Ovidrel® is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

<p><strong>Therapeutic indications</strong></p> <p>Luveris&reg; in association with a follicle stimulating hormone (FSH) preparation is Indicated for the stimulation of follicular development in women with severe LH and FSH deficiency. (<em>See clinical efficacy section</em> &ndash; <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>)</p>

**4.1 Therapeutic indications** In adult women - Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomiphene citrate. - Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as _in vitro_ fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer.

<p><strong>INDICATIONS AND USAGE</strong><br> GLUCOVANCE 250 mg/1.25 mg is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone.<br> GLUCOVANCE 500 mg/2.5 mg, 500 mg/5 mg and 1000/5mg is indicated as second-line therapy when diet, exercise, and initial treatment with a sulfonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes.</p>

**4.1 Therapeutic indications** In adult women - Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomiphene citrate. - Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as _in vitro_ fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer.

<p><u><strong>Therapeutic indications</strong></u></p> <p>Treatment of hypertension as well as treatment of coronary heart disease (angina pectoris).</p> <p>Treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ACE inhibitors, and diuretics, and optionally cardiac glycosides (for additional information see section <em>Pharmacodynamic properties</em> &ndash; <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p>